Navigation Links
Schwarz's New Epilepsy Drug Reduces Seizures

An experimental epilepsy drug, lacosamide, developed by U.S firm Schwarz has found to be potential in reducing the frequency of seizures in patients// not controlled by other drugs - the company said on Monday following the results of a phase 3 trial.

The results of the 485-patient study were presented at the North American Regional Epilepsy Congress. The results proved that epileptics treated with a 200-mg dose of the drug, lacosamide, had 14.4 percent fewer seizures than those given a placebo, while patients given a 400-mg dose had 15 percent fewer seizures than placebo-treated patients. Dizziness, headache and double vision, are considered to be the two major side effects of the drug, lacosamide - the company added.

"We are delighted that lacosamide has demonstrated efficacy in a very difficult-to-treat patient population," said Iris Loew-Friedrich, a member of Schwarz' executive board.

"This trial will be submitted to the regulatory agencies in both the European Union and the (United States) as part of the marketing authorization application for lacosamide as adjunctive therapy in adults with partial seizures," Loew-Friedrich added.

Around 2.3 million Americans suffer from epileptic seizures and about 30 percent of them require two or more drugs to control the seizures, said Mike Davis, product director for Schwarz Pharma, which is being acquired by Belgian pharmaceutical group UCB SA.

It is expected that the full results from a second Phase III trial of lacosamide will be announced early next year and the drug could be on the market within the next year or so depending on the regulatory issues. – added the report.


SRI
'"/>




Page: 1

Related medicine news :

1. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Epilepsy can be predicted
4. Epilepsy Drugs Can Enhance Risk of Birth Defects
5. Epilepsy Drug Helps Diabetic Nerve Damage
6. Epilepsy Drug May Relieve Chronic Headaches
7. More Complications Seen In Women With Epilepsy
8. Epilepsy Drugs Found To Lead To Bone Loss
9. Another Use For Epilepsy Drugs
10. Epilepsy Patients Could Benefit From Pacemakers
11. Early Surgery For Treatment Of Epilepsy Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: